The UK government has ruled out exit taxes on university spinouts, opting instead to make staying more attractive. Since 2010, over 2,000 spinouts have emerged, valued at nearly £50bn and creating around 27,000 jobs, per the Royal Academy of Engineering. Despite this success, retention is challenging.

Arm Holdings, though not a formal spinout, exemplifies the trend—originating near Cambridge, it was acquired by SoftBank and now lists in the US at a $250bn valuation. Similar fates befell Oxford-born unicorns Organ Ox (sold to Japan’s Terumo for $1.5bn) and Oxford Ionics (acquired by US-based Ion Q). Startups leave due to funding limits—UK rounds rarely exceed £30mn—while US investors offer larger checks but often require relocation.

Infrastructure also favors the US: easier access to chips, servers, power, and a regulatory path to the lucrative American market, especially for biotech. The UK is responding via the British Business Bank to boost capital, aiming to rebound VC investment from a pandemic low of £1.3bn to record levels. It also highlights domestic advantages: lab costs are roughly half those in Boston or Silicon Valley, academic talent remains strong, and most founders who sell overseas still reside in the UK—suggesting enduring appeal.